ClinicalTrials.gg
CompletedNCT03252431Updated Jul 3, 2023Results posted

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Phase 3 interventional study of F-627 and Neulasta in Breast Cancer and Neutropenia, sponsored by EVIVE Biotechnology. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by EVIVE Biotechnology · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3 study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive breast cancer receiving chemotherapy treatment.

Read the detailed description

This is a Phase III, global, two arm, open label clinical study will randomize approximately 400 female subjects (approximately 200 per arm) with Stage I - III invasive breast cancer who are to receive neoadjuvant or adjuvant myelotoxic TC chemotherapy treatment (docetaxel + cyclophosphamide, 75 and 600 mg/m2, respectively). Subjects in this study will be those who are scheduled to undergo at least four 21-day cycles of chemotherapy treatment. Subjects may be scheduled for more than 4 cycles of chemotherapy; however, study participation will be limited to a subject's first 4 cycles.

The primary objective of this study will be to evaluate the efficacy of F-627 given as a single fixed dose (20 mg) pre-filled syringe as compared to Neulasta® standard dosing (6 mg) in the first chemotherapy cycle. The primary endpoint will be the duration of grade 4 (severe) neutropenia - the number of days in which the patient has had an absolute neutrophil count (ANC \<0.5 x 10\^9/L) observed in chemotherapy cycle 1.

Approximately 24 hours after chemotherapy completion in each cycle (Day 2 of the cycle), subjects will receive one of the following treatments:

Arm 1: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.

Arm 2: 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Randomization will occur in an equal ratio (1:1) using a central randomization system (IWRS) on Day 1 of the study, the day of chemotherapy administration for the first chemotherapy cycle.

This study is open-label, however, study drug injections are to be administered separately by qualified study personnel to allow study investigators to remain blinded and perform study assessments without knowledge of treatment assignment.

02

Conditions studied

  • Breast Cancer
  • Neutropenia
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 393 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

EVIVE Biotechnology is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Show evidence of a personally signed and dated document indicating that the patient has been informed of all pertinent aspects of the trial.
  2. Females ≥18 years of age.
  3. Diagnosed with Stage I-III breast cancer.
  4. Subject is scheduled to undergo 4 cycles of or adjuvant TC chemotherapy (docetaxel, cyclophosphamide, 75, 600 mg/m2, respectively).
  5. Performance status of ≤2.
  6. WBC count ≥4.0 × 109/L, ≥11.5 g/dL and a count ≥150 × 109/L.
  7. Demonstrate adequate renal, hepatic, and cardiac function (liver function tests [ {ALT}, aspartate aminotransferase {AST}, alkaline phosphatase, and total ]) should be less than 2.5x the (ULN). Serum creatinine should be less than 1.7x ULN.
  8. All subjects must agree to use at least one of the following types of : intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  1. Subject is \<18 years of age.
  2. Disease progression has occurred while receiving a taxane regimen.
  3. Subject has undergone radiation therapy within 4 weeks of enrollment.
  4. Subject has undergone bone marrow or stem-cell transplantation.
  5. Subject has a history of prior other than breast cancer that is NOT in remission.
  6. Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e., lithium) within 6 weeks of the screening period are excluded.
  7. Subject has had chemotherapy within 180 days of screening.
  8. Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, (ECG) test, or any other relevant test.
  9. History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
  10. Unwillingness to participate in the study.
  11. Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
  12. Receiving other drugs or biologics within 1 month or five half lives of enrollment (if known), which ever is less.
  13. Any condition, which can cause splenomegaly.
  14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
  15. , AST, alkaline phosphatase, total ≥2.5x .
  16. Subject with active infection, or known to be infected with chronic active within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of .
  17. Women who are pregnant or breast-feeding.
  18. Subject known to be seropositive for , or who have had an AIDS defining illness or a known immunodeficiency disorder.
  19. Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
  20. Subjects with Sickle Cell disease
  21. Subjects with known to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    F-627

    F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.

    Drug: F-627

  • Active comparator
    Neulasta

    6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles

    Drug: Neulasta

Interventions

  • DrugF-627

    single dose pre-filled syringe

  • single dose pre-filled syringe

    Also known as: pegfilgrastim

06

What researchers measure

Primary outcomes

  1. Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1

    Eligible subjects were randomized in a 1:1 ratio. Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle. Subjects remained in their assigned treatment arm throughout the study. Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles). Grade 4 (severe) neutropenia was defined as ANC \<0.5 × 109/L within the first 12 days of chemotherapy.

    Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)

Secondary outcomes

  1. Duration in Days of Use of Intravenous Antibiotic

    The duration of use of IV antibiotics was defined as the number of days in which IV antibiotics were administered

    Time frame: across all 4 chemotherapy cycles (average 84 days)

  2. Duration in Days of Hospitalization

    The duration in days of patients been hospitalized for febrile neutropenia (FN) or any infection. Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of \>38.0°C (100.4°F) sustained for \>1 hour and ANC \<0.5 x 10\^9/L on the same day.

    Time frame: across all 4 chemotherapy cycles (average 84 days)

  3. The Number of Participants With Grade 4 Neutropenia for Chemotherapy Cycle 1

    The number of participants with grade 4 neutropenia for chemotherapy cycle 1. Grade 4 (severe) neutropenia was defined as ANC \<0.5 × 109/L within the first 12 days of chemotherapy.

    Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)

  4. The Number of Participants With Febrile Neutropenia Considering All Chemotherapy Cycles.

    The number of participants with febrile neutropenia, considering all chemotherapy cycles.

    Time frame: across all 4 chemotherapy cycles (average 84 days)

  5. The Number of Participants With Use of IV Antibiotics Considering All Chemotherapy Cycles.

    The number of participants with use of IV antibiotics, considering all chemotherapy cycles.

    Time frame: across all 4 chemotherapy cycles (average 84 days)

  6. The Number of Participants in Hospitalization for Febrile Neutropenia or Any Infection Considering All Chemotherapy Cycles

    The number of participants in hospitalization for febrile neutropenia or any infection, .

    Time frame: across all 4 chemotherapy cycles (average 84 days)

07

Results

Posted May 7, 2021

Participant flow

Participant flow — Overall Study
MilestoneF-627Neulasta
Started197196
Completed186187
Not completed119

Outcome measures

PrimaryDuration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1

Eligible subjects were randomized in a 1:1 ratio. Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle. Subjects remained in their assigned treatment arm throughout the study. Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles). Grade 4 (severe) neutropenia was defined as ANC \<0.5 × 109/L within the first 12 days of chemotherapy.

Time frame:
The first of 4, 21-day chemotherapy cycles (average 3 weeks)
Reported as:
Mean · days
Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1
daysF-627Neulasta
Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 10.2 ± 0.510.2 ± 0.45
SecondaryDuration in Days of Use of Intravenous Antibiotic

The duration of use of IV antibiotics was defined as the number of days in which IV antibiotics were administered

Time frame:
across all 4 chemotherapy cycles (average 84 days)
Reported as:
Mean · days
Duration in Days of Use of Intravenous Antibiotic
daysF-627Neulasta
Duration in Days of Use of Intravenous Antibiotic0.3 ± 1.360.1 ± 0.70
SecondaryDuration in Days of Hospitalization

The duration in days of patients been hospitalized for febrile neutropenia (FN) or any infection. Febrile neutropenia is defined as a single oral temperature of ≥38.3°C (101°F) or a temperature of \>38.0°C (100.4°F) sustained for \>1 hour and ANC \<0.5 x 10\^9/L on the same day.

Time frame:
across all 4 chemotherapy cycles (average 84 days)
Reported as:
Mean · days
Duration in Days of Hospitalization
daysF-627Neulasta
Duration in Days of Hospitalization0.1 ± 0.780 ± 0.57
SecondaryThe Number of Participants With Grade 4 Neutropenia for Chemotherapy Cycle 1

The number of participants with grade 4 neutropenia for chemotherapy cycle 1. Grade 4 (severe) neutropenia was defined as ANC \<0.5 × 109/L within the first 12 days of chemotherapy.

Time frame:
The first of 4, 21-day chemotherapy cycles (average 3 weeks)
Reported as:
Count of participants · Participants
The Number of Participants With Grade 4 Neutropenia for Chemotherapy Cycle 1
ParticipantsF-627Neulasta
The Number of Participants With Grade 4 Neutropenia for Chemotherapy Cycle 12323
SecondaryThe Number of Participants With Febrile Neutropenia Considering All Chemotherapy Cycles.

The number of participants with febrile neutropenia, considering all chemotherapy cycles.

Time frame:
across all 4 chemotherapy cycles (average 84 days)
Reported as:
Count of participants · Participants
The Number of Participants With Febrile Neutropenia Considering All Chemotherapy Cycles.
ParticipantsF-627Neulasta
The Number of Participants With Febrile Neutropenia Considering All Chemotherapy Cycles.61
SecondaryThe Number of Participants With Use of IV Antibiotics Considering All Chemotherapy Cycles.

The number of participants with use of IV antibiotics, considering all chemotherapy cycles.

Time frame:
across all 4 chemotherapy cycles (average 84 days)
Reported as:
Count of participants · Participants
The Number of Participants With Use of IV Antibiotics Considering All Chemotherapy Cycles.
ParticipantsF-627Neulasta
The Number of Participants With Use of IV Antibiotics Considering All Chemotherapy Cycles.92
SecondaryThe Number of Participants in Hospitalization for Febrile Neutropenia or Any Infection Considering All Chemotherapy Cycles

The number of participants in hospitalization for febrile neutropenia or any infection, .

Time frame:
across all 4 chemotherapy cycles (average 84 days)
Reported as:
Count of participants · Participants
The Number of Participants in Hospitalization for Febrile Neutropenia or Any Infection Considering All Chemotherapy Cycles
ParticipantsF-627Neulasta
The Number of Participants in Hospitalization for Febrile Neutropenia or Any Infection Considering All Chemotherapy Cycles11

Adverse events

Collected over AEs and SAEs were collected from the time of randomization until end of treatment visit day 84 (total of 9 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
F-6271/197 (0.5%)12/197 (6.1%)70/197 (35.5%)
Neulasta2/196 (1%)3/196 (1.5%)51/196 (26%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventF-627Neulasta
Febrile neutropeniaBlood and lymphatic system disorders2/1970/196
pneumoniaRespiratory, thoracic and mediastinal disorders2/1971/196
anemiaBlood and lymphatic system disorders0/1971/196
neutropeniaBlood and lymphatic system disorders0/1971/196
Myocardial infarctionCardiac disorders0/1971/196
Hepatitis toxicHepatobiliary disorders0/1971/196
fatigueGeneral disorders1/1970/196
diabetic ketoacidosisMetabolism and nutrition disorders1/1970/196
syncopeNervous system disorders1/1970/196
acute kidney injuryRenal and urinary disorders1/1970/196
Most frequent other events
Most frequent other events
EventF-627Neulasta
Bone painMusculoskeletal and connective tissue disorders31/19723/196
LeukocytosisBlood and lymphatic system disorders14/19710/196
AstheniaGastrointestinal disorders13/19712/196
ArthralgiaMusculoskeletal and connective tissue disorders12/1976/196

Baseline characteristics

Age, Continuous
Age, Continuous(years)F-627NeulastaTotal
Mean51.4 ± 11.8253.4 ± 11.1152.4 ± 11.50
Sex: Female, Male
Sex: Female, Male(Participants)F-627NeulastaTotal
Female197196393
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)F-627NeulastaTotal
Hispanic or Latino011
Not Hispanic or Latino197195392
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)F-627NeulastaTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White197196393
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)F-627NeulastaTotal
United States101
Bulgaria181836
Hungary232245
Russia7372145
Ukraine8284166
Weight
Weight(kg)F-627NeulastaTotal
Mean75.84 ± 16.88474.93 ± 16.87375.39 ± 16.863
Height
Height(cm)F-627NeulastaTotal
Mean162.6 ± 6.27162.2 ± 6.67162.4 ± 6.47
Basal Metabolic Index
Basal Metabolic Index(kg/m2)F-627NeulastaTotal
Mean28.72 ± 6.35828.51 ± 6.19728.62 ± 6.271
08

Study locations

1 site
  • University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC)
    Los Angeles, California 90095, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2019, 17 months.

Results were first posted in May 2021, 1 year 7 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 17 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 17, 2017
StartActual
Apr 12, 2018
Primary completionActual
Sep 25, 2019
CompletionActual
Mar 5, 2020
Results first posted
May 7, 2021
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03252431
Lead sponsor
EVIVE Biotechnology
Responsible party
Sponsor
First posted
Aug 17, 2017
Start date
Apr 12, 2018
Primary completion
Sep 25, 2019
Completion
Mar 5, 2020
Results posted
May 7, 2021
Last update
Jul 3, 2023

Study contacts

John Glaspy, MD
principal investigator · University of California at Los Angeles

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efbemalenograstim alfa

Start the discussion